Increase of plasma IgE during treatment correlates with better outcome of patients with glioblastoma

Chinese Medical Journal

Volumn 124, Issue 19, 2011, Pages 3042-3048

  Lin, Yi ^a   Jin, Qiang ^b   Zhang, Guo Zhen ^b   Wang, Yun Jie ^a   Jiang, Tao ^b   Wu, An Hua ^a   Wang, Jiang Fei ^b   Qiu, Xiao Guang ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Glioblastoma; Immunoglobulin E; Plasma; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN E;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADULT; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOGLOBULIN E; MALE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 80053513274     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.19.016     Document Type: Article

References (31)

1. Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici RM. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res 2009; 29: 5171-5184.
2. Ministry of Health of the People's Republic of China. Statistical report on public health in China 2010. (Accessed 2010 at http://www.moh.gov.cn/publicfiles/business/htmlfiles/zwgkzt/ptjnj/year2010)
3. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 2008; 18: 360-369.
4. Huang L, Jiang T, Yuan F, Li GL, Liu EZ, Wang ZC. Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors. Clin Neurol Neurosurg 2008; 110: 1020-1024.
5. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
6. van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009; 27: 5881-5886.
7. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182: 2232-2241.
8. Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol 2007; 8: 813-821.
9. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 145-159.
10. Lin Y, Jiang T, Zhou K, Xu L, Chen B, Li G, et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol 2009; 11: 468-476.
11. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2006; 12: 5698-5704.
12. Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 2007; 130 (Pt 12): 3336-3341.
13. Fukuda ME, Iwadate Y, Machida T, Hiwasa T, Nimura Y, Nagai Y, et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 2005; 65: 5190-5194.
14. Ahlbom A, Feychting M, Green A, Kheifets L, Savitz DA, Swerdlow AJ. Epidemiologic evidence on mobile phones and tumor risk: a review. Epidemiology 2009; 20: 639-652.
15. Holick CN, Smith SG, Giovannucci E, Michaud DS. Coffee, tea, caffeine intake, and risk of adult glioma in three prospective cohort studies. Cancer Epidemiol Biomarkers Prev 2010; 19: 39-47.
16. Wiemels JL, Wilson D, Patil C, Patoka J, McCoy L, Rice T, et al. IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer 2009; 125: 680-687.
17. Melbye M, Smedby KE, Lehtinen T, Rostgaard K, Glimelius B, Munksgaard L, et al. Atopy and risk of non-Hodgkin lymphoma. J Natl Cancer Inst 2007; 99: 158-166.
18. Petridou ET, Chavelas C, Dikalioti SK, Dessypris N, Terzidis A, Nikoulis DI, et al. Breast cancer risk in relation to most prevalent IgE specific antibodies: a case control study in Greece. Anticancer Res 2007; 27: 1709-1713.
19. Tsavaris N, Tsigalacis D, Kosmas C, Koufos C, Vaiopoulos G, Tzivras M, et al. Preliminary evaluation of the potential prognostic value of serum levels of immunoglobulins (IgA, IgM, IgG, IgE) in patients with gastric cancer. Int J Biol Markers 1998; 13: 87-91.
20. Schoemaker MJ, Robertson L, Wigertz A, Jones ME, Hosking FJ, Feychting M, et al. Interaction between 5 genetic variants and allergy in glioma risk. Am J Epidemiol 2010; 171: 1165-1173.
21. Wiemels JL, Wiencke JK, Patoka J, Moghadassi M, Chew T, McMillan A, et al. Reduced immunoglobulin E and allergy among adults with glioma compared with controls. Cancer Res 2004; 64: 8468-8473.
22. Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, et al. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 2007; 179: 2832-2843.
23. Fu SL, Pierre J, Smith-Norowitz TA, Hagler M, Bowne W, Pincus MR, et al. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 2008; 153: 401-409.
24. Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, et al. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol 2003; 33: 1030-1040.
25. Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 2006; 66: 4531-4541.
26. Louis D, Ohgaki H, Wiestler O, Cavenee W. WHO Classification of tumours of the central nervous system, 4th ed. Lyon: IARC; 2007.
27. Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M. History of allergies among adults with glioma and controls. Int J Cancer 2002; 98: 609-615.
28. Vojtechova P, Martin RM. The association of atopic diseases with breast, prostate, and colorectal cancers: a meta-analysis. Cancer Causes Control 2009; 20: 1091-1105.
29. Lindelof B, Granath F, Tengvall-Linder M, Ekbom A. Allergy and cancer. Allergy 2005; 60: 1116-1120.
30. Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY, et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007; 67: 7477-7486.
31. Kempuraj D, Devi RS, Madhappan B, Conti P, Nazer MY, Christodoulou S, et al. T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors. Int J Immunopathol Pharmacol 2004; 17: 57-64.